Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative ...

As ASCO 2025 commenced in Chicago on Friday 30th May, pharmaphorum headed over to the Windy City’s Willis Tower for Johnson & ...

First-line treatment with sacituzumab govitecan plus pembrolizumab showed significant improvement in PFS vs. chemotherapy ...

The International Air Transport Association said on Sunday it expects the amount of sustainable aviation fuel produced to ...

Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...